| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and cash equivalents | $52.8M+1872.7% | $2.7M-87.6% | $21.5M-19.0% | $26.5M |
| Available-for-sale securities | $63.3M | — | $57.7M+57.3% | $36.7M |
| Interest receivable | $515K | — | $387K+176.4% | $140K |
| Prepaid clinical costs | $1.0M | — | — | — |
| Convertible notes receivable, due from Cyclo | $5.2M | — | — | — |
| Other receivables | $1.2M | — | — | — |
| Accounts receivable, net of allowance for credit losses of $245 at July 31, 2025 and July 31, 2024 | $627K+47.2% | $426K+100.0% | $213K | — |
| Inventory | $281K | — | — | — |
| Prepaid expenses and other current assets | $786K+82.8% | $430K-53.0% | $914K-80.2% | $4.6M |
| Total current assets | $56.7M-21.8% | $72.5M-12.6% | $82.9M-23.4% | $108.3M |
| Property and equipment, net | $1.6M-24.7% | $2.1M+25.1% | $1.7M-4.2% | $1.8M |
| Non-current prepaid clinical costs | $1.4M | — | — | — |
| Convertible notes receivable classified as available-for-sale | $1.9M+62.1% | $1.1M | — | — |
| Goodwill | $19.9M+553.7% | $3.0M | — | — |
| Intangible assets, net | $994K-46.2% | $1.8M | — | — |
| In-process research and development | $31.6M+1904.8% | $1.6M+0.0% | $1.6M | — |
| Other assets | $34K-2.9% | $35K+288.9% | $9K-99.4% | $1.4M |
| TOTAL ASSETS | $114.1M+17.8% | $96.8M-2.0% | $98.8M-16.5% | $118.3M |
| Accounts payable | $6.9M+169.7% | $2.6M+667.6% | $333K-41.0% | $564K |
| Accrued expenses | $3.3M+83.8% | $1.8M+135.6% | $763K-59.3% | $1.9M |
| Convertible notes payable | $614K+0.0% | $614K | — | — |
| Other current liabilities | $66K-41.6% | $113K-89.0% | $1.0M+1382.6% | $69K |
| Installment note payable | $1.7M | — | — | — |
| Total current liabilities | $11.6M+54.4% | $7.5M+250.3% | $2.1M-89.8% | $21.0M |
| Accrued expenses, noncurrent | $3.9M+30.6% | $3.0M | — | — |
| Convertible notes payable, noncurrent | $78K+6.8% | $73K | — | — |
| Other liabilities | $27K+440.0% | $5K-90.9% | $55K-37.5% | $88K |
| Deferred income tax liability | $138K | — | — | — |
| TOTAL LIABILITIES | $15.7M+48.8% | $10.6M+380.6% | $2.2M-89.6% | $21.1M |
| Additional paid-in capital | $322.2M+15.0% | $280.0M+6.1% | $264.0M+0.8% | $262.0M |
| Accumulated deficit | -$232.3M-15.1% | -$201.7M-20.6% | -$167.3M-1.1% | -$165.5M |
| Treasury stock, at cost; 101,487 Class B shares as of July 31, 2025 and July 31, 2024 | -$168K+0.0% | -$168K | — | — |
| Accumulated other comprehensive income related to unrealized income on available-for-sale securities | $358K+222.5% | $111K+131.4% | -$353K-460.3% | -$63K |
| Accumulated other comprehensive income related to foreign currency translation adjustment | $3.8M+2.6% | $3.7M-0.9% | $3.7M-1.1% | $3.8M |
| Total equity attributable to Rafael Holdings, Inc. | $94.4M+14.9% | $82.2M-18.1% | $100.3M-0.2% | $100.5M |
| Noncontrolling interests | $4.0M-2.3% | $4.1M+211.2% | -$3.7M-10.7% | -$3.3M |
| TOTAL EQUITY | $98.4M+14.0% | $86.3M-10.7% | $96.6M-0.6% | $97.2M |
| TOTAL LIABILITIES AND EQUITY | $114.1M+17.8% | $96.8M-2.0% | $98.8M-16.5% | $118.3M |
| Cyclo | ||||
| Investments | $2.5M | — | $4.8M | — |
| Hedge Funds | ||||
| Related Parties | ||||
| Due to related parties | $723K-1.4% | $733K+2719.2% | $26K | — |
| Class A Common Stock | ||||
| Common stock value | $508K+113.4% | $238K+0.8% | $236K-0.4% | $237K |
| Class B Common Stock | ||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.